Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-cell Non-hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06682130
What this trial is testing

Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma(DLBCL)
The First Affiliated Hospital of Soochow University 40
Testing effectiveness (Phase 2)Ended earlyNCT00086840
What this trial is testing

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRefractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)WithdrawnNCT03098355
What this trial is testing

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Zhujiang Hospital
Testing effectiveness (Phase 2)UnknownNCT03166878
What this trial is testing

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Chinese PLA General Hospital 80
Early research (Phase 1)Ended earlyNCT01300793
What this trial is testing

Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

Who this might be right for
Non-Hodgkin's LymphomaB-cell Lymphoma
University of California, San Francisco 6
Testing effectiveness (Phase 2)Ended earlyNCT01944943
What this trial is testing

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-hodgkin LymphomaPrimary Central Nervous System Lymphoma+1 more
The Lymphoma Academic Research Organisation 31
Testing effectiveness (Phase 2)UnknownNCT01307592
What this trial is testing

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
Auxilio Mutuo Cancer Center 70
Large-scale testing (Phase 3)Active Not RecruitingNCT05171647
What this trial is testing

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Hoffmann-La Roche 208
Testing effectiveness (Phase 2)UnknownNCT05805943
What this trial is testing

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Who this might be right for
CD20-positive B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 154
Not applicableTemporarily pausedNCT03229876
What this trial is testing

Safety and Efficacy Evaluation of CD19-UCART

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Non Hodgkin Lymphoma (NHL)
Bioray Laboratories 20
Early research (Phase 1)UnknownNCT04693676
What this trial is testing

C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's B-cell Lymphoma
First Affiliated Hospital of Zhejiang University 17
Early research (Phase 1)Looking for participantsNCT06624085
What this trial is testing

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Study completedNCT00081874
What this trial is testing

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Who this might be right for
LeukemiaMantle Cell LymphomaMyelofibrosis
M.D. Anderson Cancer Center 29
Early research (Phase 1)Looking for participantsNCT07603479
What this trial is testing

JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
MalignanciesSolid Malignant TumorNHL (Non-Hodgkin Lymphoma)+1 more
Jecho Biopharmaceuticals Co., Ltd. 14
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Early research (Phase 1)UnknownNCT00004086
What this trial is testing

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

Who this might be right for
LeukemiaLymphoma
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Testing effectiveness (Phase 2)Study completedNCT01939327
What this trial is testing

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Institut Paoli-Calmettes 34
Early research (Phase 1)UnknownNCT05106946
What this trial is testing

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Who this might be right for
B-cell Malignancy
Fundamenta Therapeutics, Ltd. 20
Early research (Phase 1)UnknownNCT04026100
What this trial is testing

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 9
Testing effectiveness (Phase 2)Ended earlyNCT01434472
What this trial is testing

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Post-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+4 more
Fred Hutchinson Cancer Center 20
Next Page